When administered to mice with Zika virus, the experimental vaccine triggered the development of antibodies and promoted a response from T-cells, which are important indicators of immunization, according to a Wednesday statement from the drug maker. The vaccine, which is being developed in a South Korea lab, will soon undergo testing in non-human primates.
More than a dozen groups of researchers, including the National Institutes of Health, are working to develop a Zika vaccine, according to the World Health Organization. While a causal link between Zika virus and microcephaly, a birth defect that can result in serious developmental disorders, has not been established, a correlation between the virus in pregnant women and infants born with the condition are causing alarm worldwide.
Researchers estimate 80 percent of those infected with Zika are asymptomatic, and for some the virus may manifest with relatively standard flu symptoms. Vaccine development for Zika is further complicated by concerns about the safety of vaccinating pregnant women, according to Reuters.
More articles on Zika virus:
2 US women miscarry after contracting Zika virus while abroad
Zika update: Is Zika or the water supply to blame for spike in microcephaly?
CDC finds strongest link yet between Zika and microcephaly
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.